Krishna Institute of Medical Sciences First Quarter 2026 Earnings: Revenues Beat Expectations, EPS Lags

Krishna Institute of Medical Sciences (NSE:KIMS) First Quarter 2026 Results

Key Financial Results

• Revenue: ₹8.72b (up 27% from 1Q 2025).
• Net income: ₹786.0m (down 9.2% from 1Q 2025).
• Profit margin: 9.0% (down from 13% in 1Q 2025). The decrease in margin was driven by higher expenses.
• EPS: ₹1.96 (down from ₹2.16 in 1Q 2025).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Krishna Institute of Medical Sciences Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in India.

Performance of the Indian Healthcare industry.

The company's shares are down 1.1% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 1 warning sign for Krishna Institute of Medical Sciences that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.